SecBot SecBot
SECBOTREPLAY Home › Report › TMDX

TMDX · TransMedics reported strong fourth quarter and full year 2025 financial…

TransMedics Group, Inc. · 8-K filed Feb 24, 2026 at 16:05 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 24, 2026 at 16:05 ET

TransMedics reported strong fourth quarter and full year 2025 financial results, with revenue up 32% and 37% respectively, driven by increased utilization of its Organ Care System. Net income surged to $105.4 million in Q4 and $190.3 million for the full year, significantly boosted by a one-time $83.8 million tax benefit from the release of a valuation allowance. The company also provided 2026 revenue guidance of $727-$757 million, representing 20-25% growth.

  • Q4 2025 revenue was $160.8 million, up 32% YoY from $121.6 million in Q4 2024
  • Full year 2025 revenue was $605.5 million, up 37% YoY from $441.5 million in 2024
  • Q4 net income was $105.4 million ($2.62 diluted EPS), including an $83.8 million tax benefit
  • Full year net income was $190.3 million ($4.87 diluted EPS), including an $82.8 million tax benefit

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access